18 February 2026 in Clinical and Translational Radiation Oncology
Contouring Inguinal lymph nodes (ILNs) in anal squamous cell cancer (ASCC) remains challenging. Accurate delineation is essential to optimize treatment efficacy with sparing of organs at risk (OaRs). Garda et al. proposed a contouring guideline based on the anatomical distribution of inguinal lymphadenopathy. This study evaluates their effectiveness in ensuring adequate ILNs coverage. We retrospectively analyzed ASCC patients with radiologically positive inguinal lymph nodes treated with IMRT in our institution between 2015 and 2024. ILNs were mapped relative to the femoral vessels and delineated based on the Garda’s guidelines. Descriptive analyses were conducted. Among 46 patients with positive ILNs, 27 (59%) had cT3-T4 stage and 27 (59%) had bilateral inguinal nodal involvement. Overall, 203 ILNs were analyzed: 88% (178 nodes) were anteromedial to the femoral vessels. Garda’s CTV encompassed 182 nodes (90%), while 22 nodes (11%) across 14 patients (30%) were not covered. Most of the uncovered nodes were in the superolateral region (n = 15, 7% of all nodes), whereas 6 nodes (3%) from six patients were identified in the inferior region. Only one node was found in the superomedial quadrant, while no nodes were located posteriorly. These findings validate the proposed guidelines, confirming their effectiveness in reducing unnecessary irradiation of the posterolateral quadrant. However, coverage gaps highlight the need for further refinements to optimize target delineation. These findings offer disease-specific evidence to inform the harmonization of inguinal CTV delineation and support the development of standardized, consensus-based contouring protocols.
4 August 2026 in Radiotherapy and Oncology
Complete response (CR) after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC) is associated with improved outcomes and may enable organ-preserving strategies. The Early Regression Index (ERI) is an imaging biomarker developed to predict treatment response. THUNDER-2 trial investigated ERI-guided magnetic resonance imaging (MRI)-based adaptive dose escalation to improve CR rates in predicted non-responders. Patients with LARC underwent MRI-guided nCRT with concurrent capecitabine or 5-fluorouracil. ERI was calculated between simulation and the 10th treatment fraction. Patients with ERI ≤ 13.1 continued standard radiotherapy, whereas those with ERI > 13.1 received an adaptive boost to 60.1 Gy using online adaptive radiotherapy. CR was defined as pathological complete response (pCR) or sustained clinical complete response (cCR) at 2 years. Patients with cCR were considered for non-operative management with intensive follow-up. Sixty-two patients were enrolled (48.4% responders, 51.6% non-responders). Adaptive dose escalation increased the CR rate in non-responders from the historically expected value of approximately 3% to 21.9%, while maintaining acceptable toxicity. Responders achieved significantly higher TME (total mesorectal excision)-free survival than non-responders (38.7% vs 8.3%; hazard ratio (HR) 2.35, 95% confidence interval (CI) 1.29-4.26; p = 0.004). Two local regrowths occurred among non-responders and were successfully salvaged. ERI was the only variable significantly associated with CR in both univariate and multivariable analyses (adjusted odds ratio (OR) 0.912, 95% CI 0.840-0.990; p = 0.028). ERI-guided MRI-based adaptive dose escalation was feasible and associated with higher-than-expected CR rates in predicted non-responders, supporting personalized treatment intensification and organ-preservation strategies in LARC (THUNDER-2; NCT04815694).